Trial Profile
A Phase I, single-dose, parallel-group, open-label study evaluating the effect of renal impairment and hemodialysis on avibactam pharmacokinetics and safety in subjects with renal impairment and healthy controls.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2016
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- 05 Aug 2016 New trial record
- 12 Jul 2016 Results published in the Journal of Clinical Pharmacology